TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05131737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High altitude exposure
Description: Exposure to 2500m of altitude

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High altitude exposure
Description: Exposure to 2500m of altitude

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low altitude exposure
Description: Exposure to 490 m

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low altitude exposure
Description: Exposure to 490 m
Study: NCT05178550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: intravenous \[iv\] injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: intravenous \[iv\] injection
Study: NCT05012917

Intervention type: OTHER
Group type: OTHER
Intervention: Patient/Proxy-SSPedi
Description: SSPedi and Mini-SSPedi: SSPedi is a symptom assessment scale for children 8-18 years of age that includes 15 symptoms considered most important by children receiving cancer treatment or HSCT, their parents and healthcare professionals. Each symptom is rated on a 5-point Likert scale consisting of 0=not at all bothered, 1=a little, 2=medium, 3=a lot and 4=extremely bothered. The recall period is yesterday or today.~Mini-SSPedi was developed for children 4-7 years of age and is comprised of the same 15 symptoms. Mini-SSPedi has a recall period of today with a 3-point Likert scale consisting of 0=not at all bothered, 2=medium and 4=extremely bothered'. So, the anchors and mid-point are identical to SSPedi. A faces-type scale accompanies the response options and the symptom descriptions are simplified.~Proxy-SSPedi: Proxy-SSPedi is identical to SSPedi except that the leading question refers to your child rather than you. It is designed for children 2-18 years of age.

Intervention type: OTHER
Group type: OTHER
Intervention: Patient/Proxy-SSPedi
Description: SSPedi and Mini-SSPedi: SSPedi is a symptom assessment scale for children 8-18 years of age that includes 15 symptoms considered most important by children receiving cancer treatment or HSCT, their parents and healthcare professionals. Each symptom is rated on a 5-point Likert scale consisting of 0=not at all bothered, 1=a little, 2=medium, 3=a lot and 4=extremely bothered. The recall period is yesterday or today.~Mini-SSPedi was developed for children 4-7 years of age and is comprised of the same 15 symptoms. Mini-SSPedi has a recall period of today with a 3-point Likert scale consisting of 0=not at all bothered, 2=medium and 4=extremely bothered'. So, the anchors and mid-point are identical to SSPedi. A faces-type scale accompanies the response options and the symptom descriptions are simplified.~Proxy-SSPedi: Proxy-SSPedi is identical to SSPedi except that the leading question refers to your child rather than you. It is designed for children 2-18 years of age.
Study: NCT05902377

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-NY104 PET/CT
Description: Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration.
Study: NCT05264974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous total tumor mRNA loaded DOTAP liposome vaccine
Description: All participants will receive three doses of RNA-NP vaccine (1 dose every 2 weeks) intravenously.~The vaccine dose given will be determined by a 3 + 3 design. Participants will be given one of the following vaccine doses:~Dose level 0 (starting dose level): 0.00125 mg/kg mRNA in 0.01875 mg/kg LP; Dose level 1: 0.0025 mg/kg mRNA in 0.0375 mg/kg LP; Dose level 2: 0.005 mg/kg mRNA in 0.075 mg/kg LP; or Dose level 3: 0.01 mg/kg mRNA in 0.15 mg/kg LP~If 3 or more of the initial 6 subjects experience a dose-limiting toxicity, then the initial starting dose will be reduced (dose de-escalation) to 0.000625 mg/kg mRNA encapsulated in 0.009375mg/kg LPs (Dose level -1).
Study: NCT05890222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Intervention
Description: Community intervention strategies will be delivered by community volunteers (called Sangathis - which means companion in Konkani, one of the local languages) to i) enhance demand for the HAP treatment and ii) promote engagement with, and completion of, the HAP treatment. The community intervention is co-produced with local community members and includes strategies such as activities to increase awareness about depression (community meetings, street plays and health camps), and dissemination of psycho-educational materials (i.e., leaflets and posters), identify people with possible depression in the community, and facilitate access to HAP in the health centres. Additionally, the Sangathis will coordinate continuing care of people receiving HAP, through home visits to encourage behavioural activation, homework completion and following up with the counsellor, and engaging family members to support the patient in achieving treatment goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Activity Program (HAP)
Description: HAP includes the following strategies: psychoeducation, behavioural assessment, activity monitoring, activity structuring and scheduling, activation of social networks, and problem-solving. HAP will be delivered in an individual format. It entails three phases of treatment, delivered over six to eight sessions, each lasting up to 40 minutes, with the sessions being at weekly intervals. Sessions will be delivered face-to-face, at the health centre where the counsellors already work.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Activity Program (HAP)
Description: HAP includes the following strategies: psychoeducation, behavioural assessment, activity monitoring, activity structuring and scheduling, activation of social networks, and problem-solving. HAP will be delivered in an individual format. It entails three phases of treatment, delivered over six to eight sessions, each lasting up to 40 minutes, with the sessions being at weekly intervals. Sessions will be delivered face-to-face, at the health centre where the counsellors already work.
Study: NCT00771641

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET electron therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET photon therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study: NCT05483309

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT scan
Description: Patients receive a CT scan

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT scan
Description: Patients receive a CT scan

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FilmArray Pneumonia Panel
Description: The FilmArray Pneumonia Panel is used to analysis the patient's sputum sample for the cause of the hospital acquired pneumonia

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FilmArray Pneumonia Panel
Description: The FilmArray Pneumonia Panel is used to analysis the patient's sputum sample for the cause of the hospital acquired pneumonia
Study: NCT04762888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: PET/MRI or PET/CT
Study: NCT05909059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Received IV on Days -5 to -3 before CAR T cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Received IV on Days -5 to -3 before CAR T cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Received IV on Days -5 to -3 before CAR T cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Received IV on Days -5 to -3 before CAR T cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Received IV on Days -5 to -3 before CAR T cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Received IV on Days -5 to -3 before CAR T cell therapy
Study: NCT05388851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Complete educational training module

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT06467487

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Letter
Description: Patients receive a traditional letter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Letter
Description: Patients receive a traditional letter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct to Patient Message
Description: Patients receive a direct to patient message via the portal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct to Patient Message
Description: Patients receive a direct to patient message via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized Letter
Description: Patients receive an optimized letter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized Letter
Description: Patients receive an optimized letter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct to Patient Message - Optimized
Description: Patients receive an optimized direct to patient message via the portal.
Study: NCT05012917

Intervention type: OTHER
Group type: OTHER
Intervention: Co-SSPedi
Description: Co-SSPedi: Co-SSPedi is based upon either SSPedi (age 8-18) or mini-SSPedi (age 4-7).~Co-SSPedi is meant to be completed by both child and parent together. The format and wording is identical to self-report SSPedi and mini-SSPedi (depending on child age) to maximize the ability of the child to participate in symptom reporting.~The approach uses written instruction that asks the dyad who will hold the device and enter the agreed-upon scores. The instruction then asks one member to read the leading question, each symptom and response options out loud. The child answers how bothered they are by that symptom out loud. The parent then states if they agree or they can offer a different answer. If the answer is different, the instruction asks the dyad to discuss until they agree upon an answer. The agreed-upon answer is then entered into co-SSPedi. This process is repeated for the remaining 14 symptoms.

Intervention type: OTHER
Group type: OTHER
Intervention: Co-SSPedi
Description: Co-SSPedi: Co-SSPedi is based upon either SSPedi (age 8-18) or mini-SSPedi (age 4-7).~Co-SSPedi is meant to be completed by both child and parent together. The format and wording is identical to self-report SSPedi and mini-SSPedi (depending on child age) to maximize the ability of the child to participate in symptom reporting.~The approach uses written instruction that asks the dyad who will hold the device and enter the agreed-upon scores. The instruction then asks one member to read the leading question, each symptom and response options out loud. The child answers how bothered they are by that symptom out loud. The parent then states if they agree or they can offer a different answer. If the answer is different, the instruction asks the dyad to discuss until they agree upon an answer. The agreed-upon answer is then entered into co-SSPedi. This process is repeated for the remaining 14 symptoms.
Study: NCT05042414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Four times four minutes treadmill interval training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity training
Description: Moderate intensity treadmill training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resting
Description: No training
Study: NCT04762602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-306
Description: Administered orally QD in a 28-day continuous dosing treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-306
Description: Administered orally QD in a 28-day continuous dosing treatment cycle
Study: NCT06467487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct to Patient Message - Optimized
Description: Patients receive an optimized direct to patient message via the portal.
Study: NCT05431361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: A Registered Kinesiologist (RKin) will provide the exercise prescription, consisting of 4-5 days of aerobic exercise training and 2-3 days of resistance exercise training of major muscle groups, during a remotely delivered familiarization session using Microsoft Teams. The 60-minute remote program introduction will include a description and demonstration of all of the exercises that will follow the baseline assessment. Patients will be prescribed an individualized exercise program considering: (1) their exercise preferences, (2) their current physical capacity, (3) previous medical history, and (4) presence of underlying comorbidities, mobility, and skeletal fragility concerns \[NOTE: the location/impact of a tumour is not applicable for PROPELLER as it was in REB#5901, and is thus not included here\]. The participant will have an opportunity to execute the exercises in the remote presence of the RKin who will provide corrective feedback where applicable.
Study: NCT06062264

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal-based Video Message
Description: Video recorded by physician encouraging patients to receive influenza vaccine. Sent via the patient portal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal-based Infographic Message
Description: Infographic with information about the influenza vaccine and an image of the physician. Sent via the patient portal.
Study: NCT04830033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENO Breathe group
Description: Six weekly group online workshop sessions, led by an ENO vocal specialist. Workshops will encourage participants to take part in exercises and activities especially designed to support breathing control, providing tools for self-management of breath and anxiety. They will also have access to bespoke online digital resources, designed to support participants between sessions. These will include exercises, song sheets and audio and video materials, especially recorded by the ENO for participants on the programme.
Study: NCT05046574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stroke rehabilitative therapy sessions with therapy dog present
Description: Therapy dog will be present during stroke rehabilitative therapy sessions. This is expected to be at least three times a week per 7-day period.
Study: NCT06528691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Given orally (PO) or enterally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Given subcutaneous (SQ) or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SQ as part of recommended Bridging Therapy instead of G-CSF.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: A gross total resection or significant debulking may become possible if a response to entrectinib is seen.
Study: NCT06386640

Intervention type: OTHER
Intervention: Intervention Development
Description: Phase I: Research to inform intervention design, Phase II: Co-design and production of intervention with relevant stakeholders, Phase IIa: Physical activity accelerometer data collection and analysis to develop an individualised rehabilitation programme, Phase III: Pilot and refine the intervention across to two NHS sites (University Hospitals of Leicester NHS Trust, Portsmouth Hospitals University NHS Trust).
Study: NCT04680351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phrenic stimulation
Description: measurements of the hemodynamic effects of phrenic stimulation
Study: NCT06024681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplant
Description: Capsulised faecal microbiota transplant prepared from rationally selected donor, based upon donor metabolomic charateristics
Study: NCT06508112

Intervention type: DEVICE
Intervention: Masimo Radical-7® Pulse CO-Oximeter
Description: Masimo Radical-7® Pulse CO-Oximeter device was attached to the index finger of the patients in the supine position and photoplethysmographic perfusion index and plethysmographic variability index were measured noninvasively, rapidly and continuously.
Study: NCT04521699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CalmioGO Stress management device
Description: CalmiGo device is a device of similar size to an inhaler that uses guided breathing, and grounding techniques to regulate breathing to bring users a sense of calm and relaxation.
Study: NCT05309668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib granule formulation
Description: Selumetinib granule formulation will be administered using BSA-based dosing. The granule formulation dose schema to be used in the study will be established in the dose finding phase.~At enrolment participants must have a BSA within the range 0.40 to 1.09 m2; once participants attain a BSA between 1.10 and 1.29 m2 they will be encouraged to transition to the capsule formulation, if feasible, although all participants must remain on the granule formulation until after they have completed their third cycle of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib capsule formulation
Description: Selumetinib capsule formulation will be administered using BSA-based dosing. Once participants attain a BSA between 1.10 and 1.29 m2 they will be encouraged to transition to the capsule formulation, if feasible, although all participants must remain on the granule formulation until after they have completed their third cycle of treatment.
Study: NCT06358326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: In addition to stretching, nerve mobilization and tendon gliding exercises, a total of 5 sessions of dry needling will be performed for fascial mobilization, 2 days a week for 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The physiotherapist will teach stretching, neuromobilization and tendon shifting exercises and will be asked to do them regularly for 3 weeks.
Study: NCT04288830

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi Moving Mindfulness Meditation and Resilience Training
Description: Low-impact mind-body exercise adapted from traditional tai chi.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Moving Mindfulness Meditation and Resilience Training
Description: Low-impact mind-body exercise adapted from traditional tai chi.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Low-impact aerobic exercise, led by instructor

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Low-impact aerobic exercise, led by instructor
Study: NCT05987852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: Participants enrolled in the active intervention group receiving HBOT will undergo compression to 2.4 Atmospheres Absolute (ATA; 100% O2) for 90 minutes with two 5-10 minute air breaks (breathing room air at the 2.4 ATA) during the session. This is done once a day for 5 days.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Hyperbaric Air
Description: This control arm will undergo compression to 1.34 ATA for monoplace chambers and 2.4 ATA for multiplace chambers for the full 90-minute session but 21% oxygen instead of 100% oxygen being administered. These participants will also have two 5-10 minute air breaks to mimic the treatment protocol. Multiplace sham sessions will have modified air breaks to avoid decompression sickness. This will happen once a day for 5 days.
Study: NCT06549530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVA-BN
Description: All participants will receive 2 vaccinations of the same dose of MVA-BN vaccine 4 weeks apart (standard regimen).
Study: NCT06397807

Intervention type: DRUG
Intervention: Dinalbuphine sebacate
Description: Dinalbuphine sebacate (DS) is a long-acting injectable. With oil-based formulation, DS will slowly releases to blood vessel and be hydrolyzed to nalbuphine after intramuscularly injection. The analgesic effect lasts around 5 to 7 days.

Intervention type: DRUG
Intervention: Analgesic injectables
Description: Opioids, NSAIDs or acetamol will be administrated as need.

Intervention type: DRUG
Intervention: Analgesic injectables
Description: Opioids, NSAIDs or acetamol will be administrated as need.

Intervention type: DRUG
Intervention: Enteral analgesics
Description: Opioids, NSAIDs or acetaminophen will be prescribed if necessary.

Intervention type: DRUG
Intervention: Enteral analgesics
Description: Opioids, NSAIDs or acetaminophen will be prescribed if necessary.